Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Qiagen ( (QGEN) ) has shared an update.
QIAGEN N.V. has announced a notification from the Netherlands Authority for the Financial Markets (AFM) regarding a significant transaction involving Goldman Sachs Group Inc. The transaction, dated December 10, 2025, involves various types of shares and financial instruments, indicating Goldman Sachs’ potential and real indirect voting rights and capital interest in QIAGEN. This announcement highlights the strategic financial maneuvers by Goldman Sachs, which could impact QIAGEN’s market positioning and stakeholder interests.
The most recent analyst rating on (QGEN) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company focuses on enabling customers to gain valuable insights from the building blocks of life, such as DNA, RNA, and proteins.
Average Trading Volume: 1,171,229
Technical Sentiment Signal: Buy
Current Market Cap: $9.81B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.